Compare CPSS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | MCRB |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 139.7M |
| IPO Year | 2010 | 2015 |
| Metric | CPSS | MCRB |
|---|---|---|
| Price | $7.72 | $9.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 15.9K | ★ 42.7K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.27 | N/A |
| EPS | ★ 0.80 | 0.64 |
| Revenue | ★ $434,470,000.00 | $789,000.00 |
| Revenue This Year | $147.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.73 | $13.75 |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $6.67 | $0.36 |
| 52 Week High | $10.51 | $29.98 |
| Indicator | CPSS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 44.79 |
| Support Level | $7.47 | $7.74 |
| Resistance Level | $8.57 | $9.53 |
| Average True Range (ATR) | 0.31 | 0.68 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 30.34 | 56.90 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.